Literature DB >> 7758505

Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: can we predict the response to chemotherapy in small cell lung cancer?

J L Moretti1, M Caglar, C Boaziz, N Caillat-Vigneron, J F Morere.   

Abstract

A case of small cell lung carcinoma (SCLC) demonstrating uptake on functional indium-111 octreotide scintigraphy is presented. Technetium-99m hexakis-2-methoxyisobutylisonitrile (MIBI) scintigraphy clearly delineated an absence of radionuclide uptake at the tumour site. This suggested the presence of multidrug resistance-mediated P glycoprotein (Pgp) on tumour cells, which recognizes certain chemotherapeutic agents as well as MIBI as a substrate and avoids radionuclide concentration. Following three courses of chemotherapy, the patient failed to improve and eventually died. This case demonstrates the importance of functional images, which have the potential to predict the outcome in response to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758505     DOI: 10.1007/BF00838949

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  15 in total

Review 1.  Chemotherapy of lung cancer.

Authors:  D C Ihde
Journal:  N Engl J Med       Date:  1992-11-12       Impact factor: 91.245

Review 2.  Pharmacology of drugs that alter multidrug resistance in cancer.

Authors:  J M Ford; W N Hait
Journal:  Pharmacol Rev       Date:  1990-09       Impact factor: 25.468

3.  Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro.

Authors:  L I Delmon-Moingeon; D Piwnica-Worms; A D Van den Abbeele; B L Holman; A Davison; A G Jones
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

4.  Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.

Authors:  A F Gazdar; D N Carney; M M Nau; J D Minna
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

5.  A cross-linking assay allows the detection of receptors for the somatostatin analogue, lanreotide in human breast tumours.

Authors:  G Prévost; P Provost; V Sallé; M Lanson; F Thomas
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 6.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

7.  Somatostatin analogue scintigraphy in granulomatous diseases.

Authors:  P M Vanhagen; E P Krenning; J C Reubi; D J Kwekkeboom; W H Bakker; A H Mulder; I Laissue; H C Hoogstede; S W Lamberts
Journal:  Eur J Nucl Med       Date:  1994-06

8.  Increased accumulation of hexakis (2-methoxyisobutylisonitrile)technetium(I) in osteosarcoma and its metastatic lymph nodes.

Authors:  B Caner; M Kitapçi; T Aras; G Erbengi; O Uğur; C Bekdik
Journal:  J Nucl Med       Date:  1991-10       Impact factor: 10.057

9.  Effect of metabolic inhibition on technetium-99m-MIBI kinetics in cultured chick myocardial cells.

Authors:  D Piwnica-Worms; J F Kronauge; L Delmon; B L Holman; J D Marsh; A G Jones
Journal:  J Nucl Med       Date:  1990-04       Impact factor: 10.057

Review 10.  Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.

Authors:  C A Hoefnagel
Journal:  Eur J Nucl Med       Date:  1994-06
View more
  7 in total

1.  Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance.

Authors:  L Kabasakal; K Ozker; M Hayward; G Akansel; O Griffith; A T Isitman; R Hellman; D Collier
Journal:  Eur J Nucl Med       Date:  1996-05

Review 2.  Nuclear medicine at the crossroads.

Authors:  H W Strauss
Journal:  Eur J Nucl Med       Date:  1996-06

3.  99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between 99mTc-MIBI uptake and P-glycoprotein expression in tumour tissue.

Authors:  E Derebek; Z Kirkali; A S Dogan; B Degirmenci; M Yilmaz; E Igci; K Yorukoglu; I Kovanlikaya; H Durak
Journal:  Eur J Nucl Med       Date:  1996-08

4.  Accumulation of Tc-99m MIBI in breast lymphoma: comparison with Ga-67 citrate.

Authors:  Y Nishiyama; Y Yamamoto; Y Kawasaki; K Satoh; H Takashima; M Ohkawa; M Tanabe
Journal:  Ann Nucl Med       Date:  1996-11       Impact factor: 2.668

5.  Scintigraphic findings on 99mTc-MDP, 99mTc-sestamibi and 99mTc-HMPAO images in Gaucher's disease.

Authors:  G Mariani; N Molea; L La Civita; G Porciello; E Lazzeri; C Ferri
Journal:  Eur J Nucl Med       Date:  1996-04

6.  The use of 99mTc-MIBI scanning in multiple myeloma.

Authors:  E B Tirovola; L Biassoni; K E Britton; N Kaleva; V Kouykin; J S Malpas
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

7.  Effectiveness of Tc-99m MIBI scintigraphy in diagnosing lung cancer.

Authors:  S Tanaka; T Asao; M Ubukata; H Sugiyama; Y Yajima; S Takenoshita; Y Nagamachi
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.